ALSO IN THIS MONTH'S ISSUE

More from this month's issue

BEYOND THE PRINTED PAGE

More beyond the printed page articles

WEB-EXCLUSIVE EDITORIAL

  • Idealism Vs. Reality:  Potential Issues Impacting President’s Plan To Lower Drug Prices
    Idealism Vs. Reality: Potential Issues Impacting President’s Plan To Lower Drug Prices

    In looking at the President’s plan for lowering drug prices, a significant chasm exists between idealism and reality. While it will be important to take all factors into consideration, some key potential issues merit close attention.

  • President Trump, Communist China, and Pharma Outsourcing
    President Trump, Communist China, and Pharma Outsourcing

    President Clinton once said to reject permanent normal trade relations with China would be a mistake of hugely historic proportions. But years later will history judge “free" trade with China "a blunder of truly historic proportions from which America will never recover”? Enter Donald Trump. Our drug industry, dependent on China, should join the public discourse.

  • How To Tell If A CRA Candidate Is Lying
    How To Tell If A CRA Candidate Is Lying

    I was recently invited to speak on the subject of fraudulent candidates and fake clinical research associates (CRAs) at the Global 2018 ACRP Conference and was astonished at how many hiring managers were not aware applicant fraudulence exists. 

  • 4 Future Scenarios For Cell And Gene Therapy Adoption
    4 Future Scenarios For Cell And Gene Therapy Adoption

    Cell and gene therapies are finally becoming a reality, with hundreds of clinical trials underway and some major therapeutic breakthroughs already reaching the market. In the past year alone, the FDA approved its first gene therapy, Spark’s Luxturna for the treatment of a rare form of vision loss, as well as the first two CAR T-cell therapies, Novartis’s Kymriah and Gilead’s Yescarta, for certain forms of blood cancer. While this certainly marks the beginning of an exciting period in the development of cell and gene therapies — the culmination of decades of development — the future impact of cell and gene therapies is uncertain.

  • Is Hong Kong The New Wonder For U.S. Biotechs, Or Just Another Fad?
    Is Hong Kong The New Wonder For U.S. Biotechs, Or Just Another Fad?

    The latest country that seems to be courting the U.S. life science public offering market is China, specifically, the Hong Kong Exchange. In particular, U.S.-based life sciences companies with Chinese management teams or some other connections to China seem to be the primary target.

  • When Should Tax Functions Be Brought In-House?
    When Should Tax Functions Be Brought In-House?

    At what stage of a biopharma’s growth does it makes sense to bring on an internal tax function? The answer, of course, varies significantly, but here are some factors to consider when making this important business decision.

  • 3 Major Challenges With Global Clinical Trials — And How To Overcome Them
    3 Major Challenges With Global Clinical Trials — And How To Overcome Them

    The disconnect between increased investment/activity and output points to continuing significant challenges in the global clinical trials market. Here we examine three of the leading issues facing the biopharmaceutical industry today.

  • “China Rx” Looking For The Truth In Biopharma Outsourcing
    “China Rx” Looking For The Truth In Biopharma Outsourcing

    Outsourced Pharma is quoted in a new book, “China Rx: Exposing the Risks of America's Dependence on China for Medicine.” Award-winning author and senior advisor at The Hastings Center, Rosemary Gibson, says drug companies rely on China to the detriment of U.S. patient safety, and we’ve ceded control of drug supply chains to Chinese CMOs, and potentially an adversarial government across the Pacific.

More web-exclusive editorial

 EVENTS

Reacting to “Human Error” – Moving Beyond “Retraining” As A Response August 22 - 22, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
Measuring Medical Affairs Success – Identifying the Key Performance Indicators (KPIs) for Successful Teams August 24 - 24, 2018
1:00 PM - 2:00 PM EDT)
Duration:  60-Minutes
Price:  $199 - Includes Bonus Handouts!
Laboratory Data Integrity: Current Expectations for OOS Result Investigations August 29 - 29, 2018
1:00 PM - 2:30 PM EDT)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
LogiPharma 2018 September 5 - 6, 2018
Philadelphia, PA)
Aseptic Process Validation: Top-Tips for Compliance and Success September 10 - 10, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
More events....

AUGUST 2018 DIGITAL EDITION

BIOPHARMA MANUFACTURING EBOOK

2018 CMO & CRO AWARDS EDITIONS

   

@LIFESCILEADER1